Literature DB >> 25550441

Exercise oscillatory ventilation in patients with Fontan physiology.

Ashwin S Nathan1, Brittani Loukas1, Lilamarie Moko1, Fred Wu1, Jonathan Rhodes1, Rahul H Rathod1, David M Systrom1, Ana Ubeda Tikkanen1, Keri Shafer1, Gregory D Lewis1, Michael J Landzberg1, Alexander R Opotowsky2.   

Abstract

BACKGROUND: Exercise oscillatory ventilation (EOV) refers to regular oscillations in minute ventilation (VE) during exercise. Its presence correlates with heart failure severity and worse prognosis in adults with acquired heart failure. We evaluated the prevalence and predictive value of EOV in patients with single ventricle Fontan physiology. METHODS AND
RESULTS: We performed a cross-sectional analysis and prospective survival analysis of patients who had undergone a Fontan procedure and subsequent cardiopulmonary exercise test. Data were reviewed for baseline characteristics and incident mortality, heart transplant, or nonelective cardiovascular hospitalization. EOV was defined as regular oscillations for >60% of exercise duration with amplitude >15% of average VE. Survival analysis was performed using Cox regression. Among 253 subjects, EOV was present in 37.5%. Patients with EOV were younger (18.8±9.0 versus 21.7±10.1 years; P=0.02). EOV was associated with higher New York Heart Association functional class (P=0.02) and VE/VCO2 slope (36.8±6.9 versus 33.7±5.7; P=0.0002), but not with peak VO2 (59.7±14.3 versus 61.0±16.0% predicted; P=0.52) or noninvasive measures of cardiac function. The presence of EOV was associated with slightly lower mean cardiac index but other invasive hemodynamic variables were similar. During a median follow-up of 5.5 years, 22 patients underwent transplant or died (n=19 primary deaths, 3 transplants with 2 subsequent deaths). EOV was associated with increased risk of death or transplant (hazard ratio, 3.9; 95% confidence interval, 1.5-10.0; P=0.002) and also predicted the combined outcome of death, transplant, or nonelective cardiovascular hospitalization after adjusting for New York Heart Association functional class, peak VO2, and other covariates (multivariable hazard ratio, 2.0; 95% confidence interval, 1.2-3.6; P=0.01).
CONCLUSIONS: EOV is common in the Fontan population and strongly predicts lower transplant-free survival.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  Cheyne-Stokes respiration; Fontan procedure; cardiopulmonary exercise test; exercise; heart defects, congenital; ventilation

Mesh:

Year:  2014        PMID: 25550441     DOI: 10.1161/CIRCHEARTFAILURE.114.001749

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  5 in total

Review 1.  Exercise oscillatory ventilation: Mechanisms and prognostic significance.

Authors:  Bishnu P Dhakal; Gregory D Lewis
Journal:  World J Cardiol       Date:  2016-03-26

2.  Absence of Exertional Oscillatory Ventilation During Exercise Related to Late Adverse Outcome in Fontan Patients.

Authors:  Jun Muneuchi; Mamie Watanabe
Journal:  Pediatr Cardiol       Date:  2018-02-08       Impact factor: 1.655

Review 3.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.

Authors:  Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki
Journal:  Eur Heart J       Date:  2016-01-18       Impact factor: 29.983

4.  Prognostic power of cardiopulmonary exercise testing in Fontan patients: a systematic review.

Authors:  Sebastian Udholm; Nael Aldweib; Vibeke Elisabeth Hjortdal; Gruschen R Veldtman
Journal:  Open Heart       Date:  2018-07-03

Review 5.  Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)-Rationale and Design.

Authors:  Derek L Tran; Hannah Gibson; Andrew J Maiorana; Charlotte E Verrall; David W Baker; Melanie Clode; David R Lubans; Diana Zannino; Andrew Bullock; Suzie Ferrie; Julie Briody; Peter Simm; Vishva Wijesekera; Michelle D'Almeida; Sally E Gosbell; Glen M Davis; Robert Weintraub; Anthony C Keech; Rajesh Puranik; Martin Ugander; Robert Justo; Dominica Zentner; Avik Majumdar; Leeanne Grigg; Jeff S Coombes; Yves d'Udekem; Norman R Morris; Julian Ayer; David S Celermajer; Rachael Cordina
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.